Bluebird Closes In On First Approval For Neurodegenerative Disease Gene Therapy

 
• By Neena Brizmohun

The EU is set to be the first market to approve bluebird bio’s one-time gene therapy for cerebral adrenoleukodystrophy.

European flags in front of the Berlaymont building, headquarters of the European commission in Brussels.
bluebird's gene therapy Skysona could be approved in the EU soon • Source: Alamy

More from Europe

More from Geography